Search Results

You are looking at 11 - 20 of 260 items for :

  • "oxaliplatin" x
  • Refine by Access: All x
Clear All
Full access

Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, Avinash Ramchandani, Elena Asensio Martínez, Ana Custodio, Marcelo Garrido, Isabel Echavarría, Juana María Cano, Jose Enrique Lorenzo Barreto, Teresa García García, Felipe Álvarez Manceñido, Alejandra Lacalle, Marta Ferrer Cardona, Monserrat Mangas, Laura Visa, Elvira Buxó, Aitor Azkarate, Asunción Díaz-Serrano, Ana Fernández Montes, and Fernando Rivera

). Doses Administered in Doublets or Triplets Using the PSM-Matched Sample To estimate the possible effect of adding a third drug (anthracycline or docetaxel), oxaliplatin doses were compared in patients who received EOX (epirubicin, oxaliplatin, and

Full access

Al B. Benson III, J. Pablo Arnoletti, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Paul F. Engstrom, Peter C. Enzinger, James W. Fleshman Jr., Charles S. Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr., Constantinos T. Sofocleous, Alan P. Venook, and Christopher Willett

can be enrolled in a clinical trial, observed without adjuvant therapy, or considered for capecitabine or 5-FU/leucovorin (LV). Based on results of the MOSAIC trial, 83 – 86 and the possible long-term sequelae of oxaliplatin-based chemotherapy, the

Full access

Aparna Parikh, Chloe Atreya, W. Michael Korn, and Alan P. Venook

with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline. Next-generation sequencing (NGS) of the primary tumor identified HER2 amplification and we were able to obtain trastuzumab-DM1 for off-label use

Full access

Quisette P. Janssen, Jacob L. van Dam, Laura R. Prakash, Deesje Doppenberg, Christopher H. Crane, Casper H.J. van Eijck, Susannah G. Ellsworth, William R. Jarnagin, Eileen M. O’Reilly, Alessandro Paniccia, Marsha Reyngold, Marc G. Besselink, Matthew H.G. Katz, Ching-Wei D. Tzeng, Amer H. Zureikat, Bas Groot Koerkamp, Alice C. Wei, and for the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium

PREOPANC trial used gemcitabine alone, which was shown to be inferior to FOLFIRINOX (5-fluorouracil/leucovorin/irinotecan/oxaliplatin) in the metastatic and adjuvant setting. 11 , 12 Through extrapolation of these results, the NCCN Guidelines has included

Full access

Anurag Saraf, Hannah J. Roberts, Jennifer Y. Wo, and Aparna R. Parikh

tumors ( Figure 1 , Table 2 ). A phase II study by Fernández-Martos et al 23 investigated 108 patients with LARC randomized to SoC concurrent CAPOX (capecitabine/oxaliplatin) and RT, surgery, and adjuvant CAPOX versus TNT with CAPOX for 4 cycles

Full access

Angela Jain, Paula D. Ryan, and Michael V. Seiden

oxaliplatin (FOLFOX) with bevacizumab. Before the start of treatment, evaluation of tumor markers was notable for a carcinoembryonic antigen (CEA), alfa-feto-protein (AFP), and CA-125 levels of 644, 5149, and 16, respectively. After 6 treatments, CEA levels

Full access

Paul F. Engstrom

metastasis. Surveillance after successful resection of early-stage colon carcinoma consisted of periodic colonoscopy, physical examination, and serial carcinoembryonic antigen (CEA) determinations. Oxaliplatin was introduced as a therapeutic agent for colon

Full access

Zhi Ven Fong and Cristina R. Ferrone

horizon for patients with metastatic PDAC significantly changed with the multiagent chemotherapy regimens fluorouracil/folinic acid/irinotecan/oxaliplatin (FOLFIRINOX) 4 and gemcitabine/nab-paclitaxel, 5 respectively. Median survival for patients with

Full access

Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Christos S. Karapetis, Ashley M. Hopkins, and Michael J. Sorich

one of the fluoropyrimidines 5-FU or capecitabine. Fluoropyrimidine-based chemotherapy, given as either first-line or second-line therapy, included either irinotecan or oxaliplatin as part of multiagent combination therapy with fluoropyrimidines and

Full access

Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group

treatment, 3 – 7 and progress in the development of new agents has been slow. Many cytotoxic agents in combination with gemcitabine did not show improvement in overall survival (OS) or quality of life (QoL). 3 – 5 , 8 – 12 In 2011, irinotecan/oxaliplatin/5